Therefore, METTL3 collaborates with YTHDF1 to promote tumor progression and attenuate the efficacy of tumor therapy by targeting the SPRED2/ERK/NF-kB-STAT3 signaling pathway, highlighting the clinical possibilities of using METTL3 as a target in tumor immunotherapy. This evidence concerns the gene METTL3 and neoplasm.